Research from the past decade indicates that intravenous ketamine and intranasal esketamine (Spravato) can be effective treatments for patients suffering from depression. Both have been shown to work in patients with treatment-resistant depression who have failed standard antidepressant treatments. Esketamine is approved by the FDA and intravenous ketamine is provided off-label.
The Ketamine Clinic at Mass General combines advanced psychopharmacology expertise with years of ketamine research to offer patients and their professional providers access to intravenous ketamine and esketamine intranasal treatment.
Recently, the clinic was expanded to offer longer service hours with a new location opening on the Mass General main campus in Boston, located in the Wang building. Services at the expanded clinic will begin in late June. Patients must be 15 years or older and must be referred by a longitudinal psychiatric provider.
The MGH Ketamine Clinic is committed to advancing our knowledge and ability to treat depression by integrating clinical care and innovative research through a number of avenues:
- Consultation Services
- Ketamine intravenous infusion (IV) service
- Intranasal esketamine (Spravato) service
- Research studies focused on ketamine treatment
Learn more about the newly expanded Ketamine Clinic and refer a patient today.
Cristina Cusin, MD is the Founder and Director of the MGH Ketamine Clinic, a psychiatrist in the Depression Clinical and Research Program, and an Associate Professor in Psychiatry at Harvard Medical School. Her research and clinical work has focused on the treatment of treatment-refractory mood disorders, using innovative strategies including ketamine and deep brain stimulation.
